DK3495495T3 - Diagnostiske markører til behandling af celleproliferative forstyrrelser med telomeraseinhibitorer - Google Patents

Diagnostiske markører til behandling af celleproliferative forstyrrelser med telomeraseinhibitorer Download PDF

Info

Publication number: DK3495495T3
Authority: DK; Denmark
Prior art keywords: treatment; cell proliferative; proliferative disorders; diagnostic markers; telomerase inhibitors
Prior art date: 2012-11-30

Application number

DK18192236.0T

Other languages

English (en)

Inventor

Ekaterina Bassett

Bart Burington

Hui Wang

Kevin Eng

Original Assignee

Geron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-30

Filing date

2013-11-27

Publication date

2021-03-22

2013-03-13 Priority claimed from US13/802,035 external-priority patent/US9200327B2/en

2013-11-27 Application filed by Geron Corp filed Critical Geron Corp

2021-03-22 Application granted granted Critical

2021-03-22 Publication of DK3495495T3 publication Critical patent/DK3495495T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/91245—Nucleotidyltransferases (2.7.7)
- G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
- G01N2333/9128—RNA-directed DNA polymerases, e.g. RT (2.7.7.49)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Neurology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)

DK18192236.0T 2012-11-30 2013-11-27 Diagnostiske markører til behandling af celleproliferative forstyrrelser med telomeraseinhibitorer DK3495495T3 (da)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201261732263P	2012-11-30	2012-11-30
US201361780851P	2013-03-13	2013-03-13
US13/802,035 US9200327B2 (en)	2012-11-30	2013-03-13	Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US201361798478P	2013-03-15	2013-03-15
US201361809228P	2013-04-05	2013-04-05
EP13858528.6A EP2925889B1 (en)	2012-11-30	2013-11-27	Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Publications (1)

Publication Number	Publication Date
DK3495495T3 true DK3495495T3 (da)	2021-03-22

Family

ID=50828470

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK13858528.6T DK2925889T3 (da)	2012-11-30	2013-11-27	Diagnostiske markører til behandling af celleproliferationsforstyrrelser med telomeraseinhibitorer
DK18192236.0T DK3495495T3 (da)	2012-11-30	2013-11-27	Diagnostiske markører til behandling af celleproliferative forstyrrelser med telomeraseinhibitorer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK13858528.6T DK2925889T3 (da)	2012-11-30	2013-11-27	Diagnostiske markører til behandling af celleproliferationsforstyrrelser med telomeraseinhibitorer

Country Status (24)

Country	Link
EP (3)	EP2925889B1 (da)
JP (2)	JP6359028B2 (da)
KR (3)	KR102174763B1 (da)
CN (2)	CN111494629A (da)
AU (3)	AU2013352105B2 (da)
BR (1)	BR112015012507B1 (da)
CA (1)	CA2892445C (da)
CY (1)	CY1124140T1 (da)
DK (2)	DK2925889T3 (da)
ES (2)	ES2703914T3 (da)
HK (1)	HK1215874A1 (da)
HR (2)	HRP20181991T1 (da)
HU (1)	HUE054053T2 (da)
IL (3)	IL282112B (da)
LT (2)	LT2925889T (da)
MX (1)	MX362094B (da)
NZ (2)	NZ748624A (da)
PL (2)	PL3495495T3 (da)
PT (2)	PT2925889T (da)
RS (1)	RS61513B1 (da)
SG (1)	SG11201504209YA (da)
SI (2)	SI2925889T1 (da)
WO (1)	WO2014085632A1 (da)
ZA (2)	ZA201900759B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2645872T3 (es)	2008-10-17	2017-12-11	Geron Corporation	Método para la identificación de la sensibilidad de un paciente a la terapia de inhibición de la telomerasa
US9375485B2 (en)	2012-12-07	2016-06-28	Geron Corporation	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en)	2016-11-04	2018-05-09	Janssen Biotech, Inc.	Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
WO2018207952A1 (ja) *	2017-05-12	2018-11-15	国立大学法人九州大学	発毛及び／又は育毛用組成物
JP7401518B2 (ja) *	2018-07-31	2023-12-19	ジェロン・コーポレーション	テロメラーゼ阻害剤による治療から利益を得る可能性が高い患者を特定する方法
GB201818792D0 (en) *	2018-11-19	2019-01-02	Telonostix Ltd	Compounds for telomere length-related treatment of cancer
EP3674418A1 (en) *	2018-12-26	2020-07-01	Life Length S.L.	Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
CN114306602A (zh) *	2020-09-28	2022-04-12	中国科学院上海营养与健康研究所	靶向tert在调节皮肤及毛发色素中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5489508A (en)	1992-05-13	1996-02-06	University Of Texas System Board Of Regents	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en)	1994-07-07	1999-09-28	Geron Corporation	Mammalian telomerase
US5583016A (en)	1994-07-07	1996-12-10	Geron Corporation	Mammalian telomerase
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
US5770613A (en)	1995-09-29	1998-06-23	Geron Corporation	Telomerase inhibitors
US5767278A (en)	1995-10-06	1998-06-16	Geron Corporation	Telomerase inhibitors
US6444650B1 (en)	1996-10-01	2002-09-03	Geron Corporation	Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en)	1996-10-01	2001-07-17	Geron Corporation	Telomerase
EP0951568A1 (en)	1996-12-20	1999-10-27	Geron Corporation	Methods for detecting and inhibiting the rna component of telomerase
JPH11276182A (ja) *	1997-12-26	1999-10-12	Chugai Pharmaceut Co Ltd	逆転写酵素モチーフを有する新規遺伝子
US6331399B1 (en)	2000-05-16	2001-12-18	Isis Pharmaceuticals, Inc.	Antisense inhibition of tert expression
ES2379375T3 (es)	2002-01-31	2012-04-25	University Of Utah	Amplificación de secuencias repetitivas de ácido nucleico
US20040234961A1 (en) *	2002-04-22	2004-11-25	Fordyce Colleen A.	Telomere length determination and applications
EP3351919A1 (en)	2003-01-24	2018-07-25	University of Utah	Methods of predicting mortality risk by determining telomere length
CN100393209C (zh)	2003-09-09	2008-06-11	杰龙公司	用于端粒酶抑制的改性寡核苷酸
DK3296312T3 (da)	2004-07-02	2021-05-03	Geron Corp	Syntese af beskyttede 3'-amino-5'-phosphoramidit-nukleosidmonomerer
CA2602562C (en) *	2005-03-25	2015-07-07	Alt Solutions, Inc.	Modulation of telomere length in telomerase positive cells and cancer therapy
ATE553198T1 (de)	2005-04-15	2012-04-15	Geron Corp	Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten
ES2645872T3 (es) *	2008-10-17	2017-12-11	Geron Corporation	Método para la identificación de la sensibilidad de un paciente a la terapia de inhibición de la telomerasa
CN102439171B (zh)	2008-12-22	2017-07-14	犹他大学研究基金会	单色多重定量pcr
US20110207128A1 (en)	2010-02-16	2011-08-25	Cawthon Richard M	Methods and kits for determining biological age and longevity based on gene expression profiles
WO2012135125A1 (en)	2011-03-28	2012-10-04	Geron Corporation	Telomere length measurement in formalin-fixed, paraffin embedded (ffpe) samples by quantitative pcr

2013
- 2013-11-27 ES ES13858528T patent/ES2703914T3/es active Active
- 2013-11-27 IL IL282112A patent/IL282112B/en unknown
- 2013-11-27 NZ NZ748624A patent/NZ748624A/en unknown
- 2013-11-27 AU AU2013352105A patent/AU2013352105B2/en active Active
- 2013-11-27 EP EP13858528.6A patent/EP2925889B1/en active Active
- 2013-11-27 LT LTEP13858528.6T patent/LT2925889T/lt unknown
- 2013-11-27 PL PL18192236T patent/PL3495495T3/pl unknown
- 2013-11-27 NZ NZ708654A patent/NZ708654A/en unknown
- 2013-11-27 PL PL13858528T patent/PL2925889T3/pl unknown
- 2013-11-27 EP EP20214086.9A patent/EP3882355B1/en active Active
- 2013-11-27 DK DK13858528.6T patent/DK2925889T3/da active
- 2013-11-27 SI SI201331271T patent/SI2925889T1/sl unknown
- 2013-11-27 SI SI201331864T patent/SI3495495T1/sl unknown
- 2013-11-27 CN CN201911349502.4A patent/CN111494629A/zh active Pending
- 2013-11-27 WO PCT/US2013/072302 patent/WO2014085632A1/en active Application Filing
- 2013-11-27 CA CA2892445A patent/CA2892445C/en active Active
- 2013-11-27 EP EP18192236.0A patent/EP3495495B1/en active Active
- 2013-11-27 KR KR1020157017235A patent/KR102174763B1/ko active IP Right Grant
- 2013-11-27 PT PT13858528T patent/PT2925889T/pt unknown
- 2013-11-27 BR BR112015012507-7A patent/BR112015012507B1/pt active IP Right Grant
- 2013-11-27 MX MX2015006538A patent/MX362094B/es active IP Right Grant
- 2013-11-27 KR KR1020207031441A patent/KR102348240B1/ko active IP Right Grant
- 2013-11-27 JP JP2015545446A patent/JP6359028B2/ja active Active
- 2013-11-27 ES ES18192236T patent/ES2865446T3/es active Active
- 2013-11-27 DK DK18192236.0T patent/DK3495495T3/da active
- 2013-11-27 PT PT181922360T patent/PT3495495T/pt unknown
- 2013-11-27 CN CN201380070816.5A patent/CN104937110A/zh active Pending
- 2013-11-27 SG SG11201504209YA patent/SG11201504209YA/en unknown
- 2013-11-27 HU HUE18192236A patent/HUE054053T2/hu unknown
- 2013-11-27 RS RS20210254A patent/RS61513B1/sr unknown
- 2013-11-27 LT LTEP18192236.0T patent/LT3495495T/lt unknown
- 2013-11-27 KR KR1020217027659A patent/KR20210112394A/ko not_active Application Discontinuation
2015
- 2015-05-27 IL IL239035A patent/IL239035B/en active IP Right Grant
2016
- 2016-04-01 HK HK16103783.7A patent/HK1215874A1/zh unknown
2018
- 2018-02-13 JP JP2018022923A patent/JP2018099127A/ja active Pending
- 2018-11-27 HR HRP20181991TT patent/HRP20181991T1/hr unknown
2019
- 2019-02-06 ZA ZA2019/00759A patent/ZA201900759B/en unknown
- 2019-11-13 IL IL270636A patent/IL270636B/en active IP Right Grant
- 2019-12-18 AU AU2019283840A patent/AU2019283840A1/en not_active Abandoned
2021
- 2021-02-26 ZA ZA2021/01317A patent/ZA202101317B/en unknown
- 2021-03-17 HR HRP20210451TT patent/HRP20210451T1/hr unknown
- 2021-03-23 CY CY20211100256T patent/CY1124140T1/el unknown
2022
- 2022-04-28 AU AU2022202808A patent/AU2022202808A1/en active Pending

Also Published As

Publication number	Publication date
CA2892445A1 (en)	2014-06-05
HK1215874A1 (zh)	2016-09-23
PL2925889T3 (pl)	2019-02-28
PL3495495T3 (pl)	2021-08-30
IL239035A0 (en)	2015-07-30
EP2925889A1 (en)	2015-10-07
EP3882355C0 (en)	2023-12-20
BR112015012507B1 (pt)	2023-03-07
EP2925889A4 (en)	2016-06-15
PT2925889T (pt)	2018-12-12
IL270636B (en)	2021-04-29
LT3495495T (lt)	2021-02-25
JP2016501523A (ja)	2016-01-21
ZA202101317B (en)	2023-03-29
KR20210112394A (ko)	2021-09-14
PT3495495T (pt)	2021-03-22
HRP20210451T1 (hr)	2021-05-14
EP3495495A1 (en)	2019-06-12
RS61513B1 (sr)	2021-03-31
CN104937110A (zh)	2015-09-23
JP2018099127A (ja)	2018-06-28
CY1124140T1 (el)	2022-05-27
KR102174763B1 (ko)	2020-11-06
HUE054053T2 (hu)	2021-08-30
SG11201504209YA (en)	2015-06-29
MX362094B (es)	2019-01-07
AU2022202808A1 (en)	2022-05-19
EP3882355A1 (en)	2021-09-22
IL239035B (en)	2020-09-30
CN111494629A (zh)	2020-08-07
KR20150091491A (ko)	2015-08-11
CA2892445C (en)	2022-06-28
DK2925889T3 (da)	2019-01-02
IL282112A (en)	2021-05-31
JP6359028B2 (ja)	2018-07-18
BR112015012507A2 (pt)	2017-07-11
NZ748624A (en)	2020-08-28
NZ708654A (en)	2020-04-24
ES2703914T3 (es)	2019-03-13
AU2013352105A1 (en)	2015-06-18
EP3882355B1 (en)	2023-12-20
SI2925889T1 (sl)	2019-01-31
AU2019283840A1 (en)	2020-01-23
KR20200128446A (ko)	2020-11-12
HRP20181991T1 (hr)	2019-03-08
SI3495495T1 (sl)	2021-07-30
KR102348240B1 (ko)	2022-01-10
ZA201900759B (en)	2020-10-28
AU2013352105B2 (en)	2019-09-19
EP3495495B1 (en)	2020-12-23
LT2925889T (lt)	2018-12-27
WO2014085632A1 (en)	2014-06-05
IL282112B (en)	2022-09-01
MX2015006538A (es)	2015-09-23
ES2865446T3 (es)	2021-10-15
EP2925889B1 (en)	2018-09-05
BR112015012507A8 (pt)	2019-10-08

Publication	Publication Date	Title
DK3329884T3 (da)	2021-09-13	Implanterbar indretning til behandling af glaukom
DK2885010T3 (da)	2020-02-03	Fremgangsmåder til behandling med tauopati
DK2819602T3 (da)	2019-08-05	Kateter til behandling af atrieflagren med enkelt-virkende dobbelt afbøjningsmekanisme
DK3811943T3 (da)	2023-04-03	Forbindelse til anvendelse til behandling af øjenlidelser
DK3495495T3 (da)	2021-03-22	Diagnostiske markører til behandling af celleproliferative forstyrrelser med telomeraseinhibitorer
DK2782618T3 (da)	2020-09-07	Transplantat til anvendelse med modpulsationsindretning
DK2818241T3 (da)	2020-04-27	Fremgangsmåde til fremstilling af behandlingsapparat udstyret med katalysatorbærende honeycombstruktur
DK2844256T3 (da)	2023-03-27	Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
DK2715352T3 (da)	2019-05-20	Fremgangsmåde til vurdering af risiko for pml
DK3712264T3 (da)	2024-05-06	Cystathionin-beta-syntaseenzym til behandling af homocystinuri
DK2836460T3 (da)	2022-10-10	Fremgangsmåde til fremstilling af graphen
DK2914310T3 (da)	2020-07-27	Medicinske indretninger med coatings til forbedret ekkogenicitet
DK2906219T3 (da)	2019-10-28	Orvepitant til behandling af kronisk pruritus
LT2928477T (lt)	2019-10-10	Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
DK2705847T3 (da)	2014-10-06	Sammensætning til behandling af psoriasis
DK2807170T3 (da)	2019-05-27	Phragmalin-limonoider til behandlingen af seksuel dysfunktion
DK2828396T3 (da)	2019-05-27	Fremgangsmåde til fremstillingen af g-csf
DK2814469T3 (da)	2020-05-04	Hydrocortisonformulering med controlled release
DK2817110T3 (da)	2020-07-20	Rettefremgangsmåde med positionering af retteemnet
DK2819699T3 (da)	2019-08-12	Sammensætninger med kontrolleret frigivelse og fremgangsmåder til anvendelse deraf
DK2988750T3 (da)	2022-04-04	Anvendelse af landiololhydrochlorid til langtidsbehandling af takyarytmier
DK3473276T3 (da)	2024-01-29	Teknikker til behandling af abscesser